CUMBERLAND PHARMACEUTICALS INC (CPIX) Form 8-K — Aug 4, 2026
Cumberland Pharmaceuticals reported a Q2 2026 net loss of $4.1 million, or $(0.27) per share, versus a $0.7 million loss a year earlier, including a $3.1 million loss from continuing operations after the divested branded business was reclassified as discontinued operations. Revenue from continuing operations was just $166,458 for the quarter. The quarter was defined by the closed Strategic Transaction with Apotex Health, which acquired Cumberland's portfolio of FDA-approved brands for $100 million in cash plus $11 million for inventory and transition services.
Key figures
- Revenue
- $166,458 (Q2 2026 net revenue from continuing operations, down from $380,797 in Q2 2025)
- Total Debt
- 0
- Total Assets
- 62879694
- Cash Position
- 3862402
- Shares Outstanding
- 14983107
- Total liabilities
- 45773246
- Shareholders equity
- 17438013
- Line of credit payoff
- $5.2 million
- Special dividend paid
- July 31, 2026
- Cancer study odds ratio
- 0.21
- Phase2 programs retained
- 4
- Apotex cash consideration
- $100 million
- Metastatic deaths p value
- 0.037
- Special dividend per share
- 1.5
- Cancer study recurrence p value
- 0.09
- Metastatic recurrence placebo arm
- 5 of 10 patients (50%)
- Metastatic recurrence ifetroban arm
- 3 of 18 patients (17%)
- Apotex inventory and transition funding
- $11 million
Price after filing
Close on the filing date to close N calendar days later (from $6.73). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.